Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles:<i>in vitro</i>and<i>in vivo</i>evaluation

Çetin, Meltem; Aktaş, Mustafa Sinan; Vural, İmran; Öztürk, Murat

doi:10.3109/02652048.2011.635426

Cited by 30 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uptake and transport studies on Caco-2 cells confirmed these results and showed that binding and transcellular transport of LMWH was higher for RS and RS/PLGA NPs than for PLGA NPs. Cetin et al (2010Cetin et al ( , 2011Cetin et al ( , 2012 [49][50][51] have developed PLGA NPs coated with several Eudragit ® polymers or PLGA-Eudragit ® blends to control the release profiles of small therapeutic molecules such as sodium diclofenac or metformin hydrochloride while for big proteins such as salmon calcitonin (sCT). These blends can increase oral bioavailability.…”

Section: Methacrylates (Eudragit ® )mentioning

confidence: 99%

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

Martín-Banderas¹,

Durán‐Lobato²,

Muñoz-Rubio³

et al. 2013

Mini Reviews in Medicinal Chemistry

View full text Add to dashboard Cite

This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either by coating the nanoparticle surface with stabilizing hydrophilic bioadhesive polymers or surfactants, or by incorporating biodegradable copolymers containing a hydrophilic moiety. Some substances such as chitosan, vitamin E, methacrylates, lectins, lecithins, bile salts and RGD molecules are employed for this purpose. Of especial interest are nanoparticles production methods and, in order to improve oral bioavailability, the mechanism of each additive.

show abstract

Section: Methacrylates (Eudragit ® )mentioning

confidence: 99%

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

Martín-Banderas¹,

Durán‐Lobato²,

Muñoz-Rubio³

et al. 2013

Mini Reviews in Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…Salmon calcitonin is a peptide that causes a decrease in blood calcium levels and is used for the treatment of bone diseases such as osteoporosis [116]. When encapsulated in Eudragit®-PLGA NPs, it was able to be administered orally to rats and achieve a greater decline in blood calcium levels for 24 hrs compared with subcutaneous injections of free salmon calcitonin [117]. Finally, cyclosporine is a potent immunosuppressive agent used for the prevention of graft rejection [118].…”

Section: Applicationsmentioning

confidence: 99%

Polymeric nanoparticle drug delivery technologies for oral delivery applications

Pridgen¹,

Alexis²,

Farokhzad³

2015

Expert Opinion on Drug Delivery

219

128

View full text Add to dashboard Cite

Introduction Many therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles are one technology being developed to enable clinically feasible oral delivery. Areas covered This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal barriers using polymeric nanoparticles will be considered, including mucoadhesive biomaterials and targeting of nanoparticles to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations. Expert opinion There have been many approaches used to overcome the transport barriers presented by the gastrointestinal tract, but most have been limited by low bioavailability. Recent strategies targeting nanoparticles to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and nanoparticles across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric nanoparticle technologies and enable the translation of these technologies to clinical practice.

show abstract

“…Therefore, it is important to 17 design feasible and effective peptide ligand modified SLNs to improve the oral 18 bioavailability of protein drugs and evaluating the influence of mucus. 19 Recently, two categories of peptide ligands were applied: epithelium targeting 20 peptide and permeation enhancing peptide. A CSKSSDYQC (CSK) peptide was 21 found to be an effective ligand exhibiting high affinity with goblet cells on the 22 epithelium [4].…”

Section: Introductionmentioning

confidence: 99%